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Introduction: Advances in endovascular interventions have expanded the options available for the invasive treatment of
lower extremity peripheral arterial disease (PAD).Whether endovascular interventions substitute for conventional bypass
surgery or are simply additive has not been investigated, and their effect on amputation rates is unknown.
Methods:We sought to analyze trends in lower extremity endovascular interventions (angioplasty and atherectomy), lower
extremity bypass surgery, and major amputation (above and below-knee) in Medicare beneficiaries between 1996 and
2006. We used 100% samples of Medicare Part B claims to calculate annual procedure rates of lower extremity bypass
surgery, endovascular interventions (angioplasty and atherectomy), and major amputation between 1996 and 2006.
Using physician specialty identifiers, we also examined trends in the specialty performing the primary procedure.
Results: Between 1996 and 2006, the rate of major lower extremity amputation declined significantly (263 to 188 per
100,000; risk ratio [RR] 0.71, 95% confidence interval [CI] 0.6-0.8). Endovascular interventions increased more than
threefold (from 138 to 455 per 100,000; RR  3.30; 95% CI: 2.9-3.7) while bypass surgery decreased by 42% (219 to
126 per 100,000; RR  0.58; 95% CI: 0.5-0.7). The increase in endovascular interventions consisted both of a growth
in peripheral angioplasty (from 135 to 337 procedures per 100,000; RR  2.49; 95% CI: 2.2-2.8) and the advent of
percutaneous atherectomy (from 3 to 118 per 100,000; RR  43.12; 95% CI: 34.8-52.0). While radiologists performed
the majority of endovascular interventions in 1996, more than 80% were performed by cardiologists and vascular
surgeons by 2006. Overall, the total number of all lower extremity vascular procedures almost doubled over the decade
(from 357 to 581 per 100,000; RR  1.63; 95% CI: 1.5-1.8).
Conclusion: Endovascular interventions are now performed much more commonly than bypass surgery in the treatment
of lower extremity PAD. These changes far exceed simple substitution, as more than three additional endovascular
interventions were performed for every one procedure declined in lower extremity bypass surgery. During this same time
period, major lower extremity amputation rates have fallen by more than 25%. However, further study is needed before
any causal link can be established between lower extremity vascular procedures and improved rates of limb salvage in
patients with PAD. (J Vasc Surg 2009;50:54-60.)Lower extremity peripheral arterial disease (PAD) af-
fects over 8 million Americans, with significant associated
morbidity andmortality.1-5 Until recently, the treatment of
these patients primarily consisted of peripheral arterial by-
pass surgery, such as femoral-popliteal bypass.3 However,
advances in catheter-based technology have made endovas-
cular interventions, such as balloon angioplasty or percuta-
neous atherectomy (removal of intra-arterial plaque using
catheter-based devices) a commonly utilized alternative.3,6
In fact, many physicians now advocate an “endovascular
first” strategy.7-9
This change has occurred in the setting of limited and
often conflicting evidence. For example, in the early 1990s,
population-based data from Maryland led many vascular
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54surgeons to argue that the use of angioplasty was not
effective, and instead resulted in even higher utilization of
peripheral bypass surgery.10 In contrast, the only random-
ized trial prospectively comparing the effectiveness of en-
dovascular interventions with open surgery reported similar
short-term outcomes between the two treatments.7 None-
theless, while many believe a shift towards endovascular
interventions has occurred, two uncertainties remain. First,
it is not yet known if endovascular interventions are per-
formed as a substitute for bypass surgery, or in addition to
bypass surgery. Second, it is unknown if these temporal
changes in the use of lower extremity revascularization
(both open and endovascular) have also been associated
with changes in the incidence of major lower extremity
amputation.
To further examine changes in utilization of endovas-
cular interventions, as well as its relationship to rates of
bypass surgery and major amputation, we examined recent
trends in lower extremity vascular procedures in the United
States using the national Medicare claims database.
METHODS
Database and subjects. We studied all Medicare claims
from theCenters forMedicare andMedicaid Services between
1996 and 2006, using the Medicare Physician/Supplier Pro-
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Part B claims from all insurance carriers. Codes including a
50 modifier represented a procedure done on both sides
of the body; therefore, any code with this modifier was
multiplied by two in order to account for each limb. Given
that the absolute size of the Medicare population remained
stable over the study period, (31.7 million beneficiaries
in 1996, 31.9 million beneficiaries in 2006, absolute
change  0.4%), as well as our limited ability to adjust for
patient co-morbidity burden, we presented only unad-
justed data in our current analysis reported per 100,000
beneficiaries. We obtained permission from the Institu-
tional Review Board at Dartmouth Medical School’s Cen-
ter for the Protection of Human Subjects to perform our
analyses.
The unit of analysis in this study was the procedure. A
single patient may undergo multiple procedures (endovas-
cular interventions, open bypass surgery, or amputation)
over the years in our analysis, on their right or left lower
extremity. However, only one procedure per patient per
day was entered into our analysis dataset. Data from our
regional quality improvement initiative, the Vascular Study
Group of Northern New England (VSGNNE), suggests
that approximately 10% of patients will undergo more than
one revascularization procedure during a time period sim-
ilar to this interval.12
Analysis of lower extremity revascularization rates.
Rates of lower extremity revascularization procedures were
examined between 1996 and 2006, according to Current
Procedural Terminology (CPT) codes13 listed in Table I.
To allow for comparison over time, annual rates were
normalized to reflect incidence rates per 100,000Medicare
beneficiaries. To examine changes over time, we calculated
risk ratios (RRs) and 95% confidence intervals (CIs), using
1996 as the referent year. All analyses were performed using
Microsoft Excel (Redmond, Wash) and STATA (College
Station, Tex).
These procedures were further categorized as either
lower extremity bypass surgery or endovascular interven-
tions. Bypass procedures included in our analysis were
aortobifemoral bypass, femoral-femoral crossover grafts, as
well as lower extremity bypass operations such as femoral-
popliteal bypass or femoral-tibial bypass, with both native
or prosthetic conduit. Because fewer than 1000 axillary-
femoral procedures were done in any year, these were not
included in the analysis. Patients who underwent combined
or hybrid procedures, such as a femoral-popliteal bypass
with an iliac angioplasty above the bypass, were coded as
open procedures. We did not include endovascular inter-
ventions consisting only of stent placement without angio-
plasty, as procedural codes for stent placement alone are
not specific for the site where the stent was placed (ie, upper
extremity, lower extremity, or visceral).
Analysis of major amputations. Rates of major am-
putations, defined as above-knee or below-knee amputa-
tion, (coded according to current procedural terminology
[CPT] codes listed in Table I) were examined over the
study period. Given that lesser amputations at the metatar-sal or single toe level are not generally considered failures of
limb salvage, amputations at lesser levels were not included
in this analysis. To allow for comparison over time, annual
rates were again normalized to reflect incidence rates per
100,000 Medicare beneficiaries, and RRs were calculated
similarly as above. We assumed that the proportion of
major lower extremity amputation due to peripheral vascu-
lar disease remained constant over the study period, as prior
analyses have demonstrated that fewer than 15% of major
lower extremity amputations are traumatic in nature, and
little change has occurred in the incidence of traumatic
amputation in recent years.14,15
Specialty designation analysis. Specialty designation
of the physicians performing the procedures during the
study period was taken from the Medicare Part B file. It is
important to note that this designation represents a self-
reported label, and does not necessarily imply subspecialty
board certification or practice patterns. For endovascular
interventions, we also considered the four most commonly
occurring specialties: vascular surgery, general surgery, car-
diology, and radiology (both diagnostic and interven-









Aortobifemoral bypass 35646 59,797
Femoral-femoral bypass 35661 55,328
Femoral-popliteal bypass:
Vein 35556 88,278
In situ 35583 40,322
Other than vein 35656 20,948
Femoral-tibial bypass:
Vein 35566 85,765
In situ 35585 64,799
Other than vein 35666 34,662
Major amputation
Above knee
Thigh, through femur, any level 27590 282,067
Thigh, through femur, with immediate
prosthetic 27591 1,820
Thigh, through femur, any level
guillotine 27592 4,748
Below knee
Leg, through tibia and fibula 27880 235,222
Leg, through tibia and fibula with
immediate prosthetic 27881 12,436









Tibioperoneal trunk and branches 35470 89,528
CPT, Current Procedural Terminology.tional). We reasoned that most general surgeons who per-
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surgery as well, and therefore we analyzed both general and
vascular surgeons collectively.
RESULTS
Lower extremity revascularization. The use of en-
dovascular interventions grew substantially between 1996
and 2006 (138 to 455 procedures per 100,000, RR 
3.30; 95% CI: 2.9-3.7), while bypass surgery decreased by
42% (219 to 126 per 100,000; RR  0.58; 95% CI:
0.5-0.7) (Fig 1). The concomitant rise of 317 per 100,000
endovascular interventions and decline of 93 per 100,000
bypass surgeries suggest that more than three new endo-
Fig 1. Trends in endovascular interventions, major amp
Risk ratio; CI, confidence interval.
Fig 2. Trends in endovascular interventions (peripheral
Risk ratio; CI, confidence interval.vascular interventions replaced each bypass surgery. Over-all, the total number of all lower extremity vascular proce-
dures almost doubled over the decade (from 357 to 581 per
100,000; RR  1.63; 95% CI: 1.5-1.8).
In addition to an overall rise in the rate of endovascular
interventions, the characteristics of these procedures changed
as well. Peripheral angioplasty was the most commonly per-
formed endovascular intervention, increasing from 135 to
337 interventions per 100,000 (RR2.49; 95%CI: 2.2-2.8).
However, in addition to angioplasty, percutaneous atherec-
tomy increased over the 10-year study period by 43-fold (3 to
118 interventions per 100,000; RR  43.12; 95% CI: 34.8-
52.0). As shown in Fig 2, percutaneous atherectomy was
performed in addition to, not as a substitute for, peripheral
n, and lower extremity bypass surgery, 1996-2006.RR,
plasty and percutaneous atherectomy), 1996-2006.RR,utatioangioangioplasty, as rates of both procedures rose steadily between
1ialty,
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vascular interventions changed over time as well, with fewer
iliac andmore tibial interventions performed later in the study
period (Table II).
Major amputation. A distinct decline in the population-
based rates of major lower extremity amputation occurred
between 1996 and 2006 (Fig 1). Overall, the rate of below-
and above-knee amputation decreased from 263 to 188
amputations per 100,000 Medicare beneficiaries, a 29%
decline (RR 0.71, 95% CI 0.6-0.8). This decline began in
2000, and remains progressive throughout the next 6 years.
Results were not different if above-knee amputations were
studied distinctly from below-knee amputations as both
decreased in similar magnitude.
Changes in provider specialty. Lastly, we examined
changes in the operating physician across endovascular
interventions in our study. The number of endovascular
interventions performed by cardiologists (29 to 170 inter-
ventions per 100,000Medicare beneficiaries, RR 5.84, 95%
CI 4.9-6.80) and vascular surgeons (12 to 162 interven-
tions per 100,000 Medicare beneficiaries, RR 13.80, 95%
CI 16.4-11.4) increased over the study period, whereas the
number of interventions performed by radiologists re-
mained relatively constant (85 to 82 interventions per
Table II. Distribution of endovascular procedures, by yea
Procedure 1996 1997 1998 1999
Angioplasty
Iliac 52 58 64 69
Femoral-popliteal 69 74 76 78
Tibial 15 15 16 16
Atherectomy
Iliac 0 0 0 0
Femoral-popliteal 2 2 1 2
Tibial 1 1 1 0
Fig 3. Trends in endovascular interventions, by spec100,000 Medicare beneficiaries, RR 0.97, 95% CI 0.94-1.01) (Fig 3). Because the growth in endovascular inter-
ventions occurred exclusively among cardiologists and
vascular surgeons, the proportion of all endovascular inter-
ventions performed by radiologists declined over time
(Fig 4). As shown in Fig 4, radiologists performed nearly
70% of all endovascular interventions in 1998.However, by
2006, they performed less than 20% of all endovascular
interventions.
DISCUSSION
In our national analysis of major lower extremity am-
putation and revascularization rates in Medicare beneficia-
ries with PAD, we found a large decline in amputations that
is paralleled bymajor changes that the location, techniques,
and providers of lower extremity revascularization have
changed significantly in the last decade. Bypass surgery was
utilized less often, while endovascular interventions flour-
ished. Cardiologists and vascular surgeons have become the
specialists most commonly providing endovascular inter-
ventions. But, perhaps most importantly, the rate of in-
crease in endovascular interventions far outpaced the de-
cline in bypass surgery. More than three endovascular
interventions were performed for every one fewer bypass
surgery during the study period, and overall, the total
anatomic location, per 100,000 Medicare beneficiaries
0 2001 2002 2003 2004 2005 2006
78 76 75 78 87 91
88 93 107 129 154 184
19 21 25 32 45 62
0 1 0 1 2 2
2 3 5 21 56 78
1 1 2 8 25 39






1number of lower extremity revascularization procedures
venti
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causally related to the change in amputation rates remains
unknown.
Why have endovascular interventions grown so rapidly?
Several explanations are possible. First, given the less inva-
sive nature of these newer techniques, a group of patients
previously untreated with surgical bypass may now be re-
ceiving endovascular interventions. Patients with severe
PAD judged too ill for surgical bypass, who in the time
period prior to aggressive utilization of endovascular tech-
nology would have undergone either no treatment or am-
putation, now likely undergo at least one, if not several,
episodes of endovascular intervention before resorting to
surgical therapy or amputation. Similarly, patients whose
symptoms are limited to claudication, whom in the past
may have deferred surgery because of its associatedmorbid-
ity, may now be eligible for endovascular intervention
because “it is only a needle puncture.”16 A decrease in the
threshold for intervention, both in claudicants and in pa-
tients with critical limb ischemia, likely represents a major
contribution to the increase in utilization.9,17,18 Similarly,
many suspect that rising awareness of PAD19 has contrib-
uted to the increase in utilization of lower extremity revas-
cularization.
Second, it is possible that endovascular interventions
are less durable, requiring patients to have several “mainte-
nance” endovascular procedures as opposed to one lower
extremity bypass. Bypass graft and stent patency rates in the
treatment of superficial femoral artery disease would sup-
port this idea, as often results of angioplasty and stent-
ing9,17 are less durable than surgical bypass.20 Therefore,
repeat procedures may be necessary for endovascular inter-
ventions to achieve a similar result when compared to
surgical bypass. However, as with the coronary circulation,
given the less invasive nature of endovascular interventions,
Fig 4. Proportion of endovascular interpatients may perceive this as an acceptable tradeoff.21Third, provider profiles among physicians treating
PAD of the lower extremity have changed. Vascular sur-
geons who once provided only surgical therapy, now al-
most universally offer endovascular interventions and
bypass surgery.22,23 Invasive cardiologists effective in trans-
lating lessons learned in the coronaries to the periphery,24
have identified the treatment of PAD as an important
element of cardiovascular care. Lastly, competition and
variation between treatment providers has also likely played
a role in the expansion of endovascular interventions.25
Is more common use of the invasive treatments of PAD
making the care of patients with PAD better? The answer
remains unknown, and for several reasons, it will be difficult
to determine. First, in contrast to coronary care, where
mortality is an important, easily measured, and broadly
applicable outcome, the outcome measures of interest in
PAD vary according to the indication for intervention. For
example, among claudicants, walking distance and freedom
from recurrence are the outcomes of interest.26 However,
in patients with critical limb ischemia, amputation-free
survival is an important outcome, as are other functional
measures such as ambulatory status and independent liv-
ing.27
Some may conclude that the data presented here sug-
gests that the increase in utilization of endovascular inter-
ventions has improved the care of patients with lower
extremity PAD, by decreasing amputation rates. However,
this conclusion cannot be directly established, and is overly
simplistic in nature. In patients with PAD, invasive therapy
alone is not the sole determinant of the success of an
intervention. Critical evaluation of interventions and their
outcome must also consider the treatment of comorbidities,
such as hyperlipidemia, diabetes, heart disease, and tobacco
abuse,19,28 as well as the influence of podiatric care. Many
have demonstrated that successful management of these con-
ons performed by specialty, 1996-2006.ditions is associated with improvements in the results of both
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must take into consideration the influence of these covariates
when deciding if and why the care of PAD is improving.
Between 1996 and 2006, we found that Medicare patients
receive more diabetics podiatric visits (increased by 360%),
as well as more testing for glycosylated hemoglobin (in-
creased by 319%) and hyperlipidemia (increased by 168%).
These changes are on a time course and magnitude similar
to that of endovascular interventions. Therefore, it is overly
simplistic, and likely incorrect, to attribute all the improve-
ment in vascular care to the increase in use of endovascular
interventions.
Therefore, what is making amputation rates fall? The
answer remains elusive, but several investigators have begun to
examine these relationships. Al-Omran, in a population-based
cohort study of nearly 16,000 patients in Ontario, examined
survival and amputation-free survival in patients undergoing
open and endovascular lower extremity revascularization, and
found lower odds of amputation or death in those under-
going angioplasty, although the authors admit limitations
in adjustment for patient characteristics and the specifics of
the procedures.33 In a regional analysis using instrumental
variables analysis, an econometric measure designed to
measure the impact of new treatments while accounting for
patient characteristics and treatment selection bias, Ho et al
suggests that increasing use of angioplasty in a region may
be related to lower amputation rates.34 But wide-spread
agreement on the effect of angioplasty on amputation rates
is not uniform; Anderson et al, using the Nationwide
Inpatient Sample, found little change in amputation rates
between 1980 and 2000, while the use of endovascular
interventions increased 10-fold.6 It is important to note,
however, that this particular analysis leaves out the years
after 2000, the time period in our work that demonstrated
the greatest decline in amputation rates.
Our future work aims to explore the relationships
among all of these treatments to allow us to learn just how
much of the decrease in amputation rates can be attributed
to each therapy. Even though it will be challenging, the
effectiveness of endovascular interventions must be criti-
cally evaluated. Few trials comparing bypass and endovas-
cular interventions have been performed in patients with
claudication,35,36 and only a single trial has been performed
in patients with critical limb ischemia.7 Certainly larger and
broader clinical trials, as well as risk-adjusted population-
based studies, are needed to critically examine the result of
lower extremity revascularization and determine which pa-
tient characteristics, invasive procedures, and medical ad-
juncts result in the best functional outcomes in patients
with PAD.
Our analysis has several limitations. First, precise details
about the indication for surgery lie deeper within our
administrative dataset than our current work describes. We
presume that approximately one-quarter of patients have
undergone open revascularization for claudication and
three-quarters for critical ischemia, given results from pre-
vious large clinical datasets.12,37 Testing this assumption
will require algorithms to discern clinical detail from ad-ministrative data, because defining a patient as having clau-
dication or critical ischemia can be accomplished by a
variety of coding options; our future work will pursue this
task. Second, the unit of analysis in our study is the proce-
dure, not the patient; it is likely that many patients have
undergone multiple procedures. Estimates from our re-
gional vascular surgery registry12 suggest that repeat pro-
cedures occur in approximately 10% of patients, and our
future work on national data will address this issue more
directly in both open and endovascular interventions. And
lastly, the nature of this analysis is a descriptive depiction of
national, “real-world” use of revascularization procedures
obtained from billing data. The weaknesses of administra-
tive data, especially in the use of risk adjustment for deter-
mining outcomes, have been well described.38,39However,
many have questioned the relative importance of these
weaknesses40 and described analytic methods to defer the
impact of these difficulties.41 Therefore, our future work
aims to use many of these strategies to gain insight into the
nature and causes of changes in revascularization and am-
putation in the national Medicare population.
In the current era, cost and efficacy play an ever-
increasing role in the design and implementation of our
national health care system for patients over age 65. In a
time period when medical errors and unexplained varia-
tions in care dominate the medical and lay literature, reduc-
tion in major limb amputations means that a greater pro-
portion of our seniors with peripheral vascular disease are
staying out of nursing homes and continuing to live inde-
pendent, mobile lives. While a direct causative link between
peripheral intervention and limb salvage remains elusive,
accurate elucidation of this relationship will help patients,
providers, payers, and policymakers evaluate the effective-
ness of the use of open and endovascular therapy in patients
with PAD.
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